Stepan Company (SCL) 17th Annual Midwest IDEAS Conference summary
Event summary combining transcript, slides, and related documents.
17th Annual Midwest IDEAS Conference summary
27 Aug, 2026Company overview and market positioning
Operates for 90 years as a leader in specialty and intermediate chemicals, serving diverse markets globally with 19 facilities in 11 countries.
Main product lines are Surfactants (70% of sales), Polymers (25%), and Specialty Products, each targeting different end markets including consumer, industrial, agriculture, and pharma.
Regional supply chain model reduces freight costs and exposure to tariffs and supply chain instability.
Strategic pillars and growth drivers
Four main strategic pillars: customer-focused solutions, innovation, diversified growth, and operational excellence, all aimed at superior shareholder return.
Innovation is tightly linked to customer needs, with 230 scientists and 14 application centers; 10% of annual sales come from new products.
Diversification targets faster-growing, higher-margin segments such as oil field services, agriculture, and tier 2/3 customers.
75% of EBITDA now comes from priority growth segments outside legacy Surfactants commodities.
Operational excellence and Project Catalyst
Project Catalyst aims for $100 million in savings over two years (60% in 2026, 40% in 2027) through footprint optimization, operational efficiencies, and organizational design.
Actions include closing legacy sites, consolidating production in efficient facilities like Pasadena, Texas, and reducing 100 roles.
Pasadena plant expected to reach 80% utilization by year-end, supporting insourcing and cost savings.
Latest events from Stepan Company
- Q2 2026 adjusted EBITDA rose 45% to $74.4M on strong segment growth and margin recovery.SCL
Q2 2026 - Net loss of $41.4M driven by restructuring, with adjusted EBITDA down 14% and sales up 2%.SCL
Q1 2026 - 2025 results highlight diversified growth, operational excellence, and a robust innovation pipeline.SCL
Investor presentation - Proxy covers director elections, pay practices, auditor ratification, and strong governance.SCL
Proxy filing - Adjusted EBITDA grew 6% in 2025; Project Catalyst targets $100M in savings, with H2 2026 recovery expected.SCL
Q4 2025 - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 2024 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 2024 - Net income up 42% and EBITDA up 12% on strong surfactant and specialty growth.SCL
Q1 2025 - Net income up 25% and adjusted EBITDA rose 4%, with Pasadena facility to boost 2025 growth.SCL
Q4 2024